Yeast extract inhibits the proliferation of renal cell carcinoma cells via regulation of iron metabolism

Moon,Daeun; Kim,Jinu; Yoon,Sang‑Pil

doi:10.3892/mmr.2019.10593

Yeast extract inhibits the proliferation of renal cell carcinoma cells via regulation of iron metabolism

Authors:
- Daeun Moon
- Jinu Kim
- Sang‑Pil Yoon
View Affiliations

Affiliations: Department of Anatomy, School of Medicine, Jeju National University, Jeju 63243, Republic of Korea
Published online on: August 20, 2019 https://doi.org/10.3892/mmr.2019.10593
Pages: 3933-3941

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The microbiome has recently attracted research interest in a variety of subjects, including cancer. In the present study, it was determined that reinforced clostridium media (RCM) for microbiome culture, exerts antitumor effects on renal cell carcinoma cells when compared to the microbiome ‘X’. The antitumor effects of RCM were investigated for all ingredients of RCM, and the results revealed that yeast extract could be a candidate for the ingredient driving this phenomenon. Further experiments including MTT assay, cell counting, cell death analysis, cell cycle analysis and western blotting were conducted with yeast extract on renal cell carcinoma cells (Caki‑1 and Caki‑2) and normal human proximal tubular cells (HK‑2). As a result, yeast extract exhibited dose‑dependent antitumor effects on Caki‑1 and Caki‑2, but only slight effects on HK‑2. In addition, yeast extract only exhibited slight effects on necrosis, autophagy, or apoptosis of Caki‑1 and Caki‑2. Yeast extract produced cell cycle arrest with an increased G0/G1 fraction and a decreased S fraction, and this was considered to be related to the decreased cyclin D1. Although yeast extract treatment increased anti‑oxidant activities, the antitumor effects of yeast extract were also related to iron metabolism, based on the decreased transferrin receptor and increased ferritin. In addition, decreased GPX4 may be related to iron‑dependent cell death, particularly in Caki‑2. These results revealed that yeast extract may inhibit proliferation of renal cell carcinoma cells by regulating iron metabolism. Since an increased iron requirement is a classic phenomenon of cancer cells, yeast extract may be a candidate for adjuvant treatment of renal cell carcinoma.

View Figures

View References

1	Inamura K: Renal cell tumors: Understanding their molecular pathological epidemiology and the 2016 WHO classification. Int J Mol Sci. 18(pii): E21952017. View Article : Google Scholar : PubMed/NCBI
2	Koo KC and Chung BH: Epidemiology and treatment patterns of urologic cancers in Korea. Korean J Urol Oncol. 13:51–57. 2015.
3	Rini BI, Rathmell WK and Godley P: Renal cell carcinoma. Curr Opin Oncol. 20:300–306. 2008. View Article : Google Scholar : PubMed/NCBI
4	Compare D and Nardone G: Contribution of gut microbiota to colonic and extracolonic cancer development. Dig Dis. 29:554–561. 2011. View Article : Google Scholar : PubMed/NCBI
5	Pope JL, Tomkovich S, Yang Y and Jobin C: Microbiota as a mediator of cancer progression and therapy. Transl Res. 179:139–154. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ramezani A and Raj DS: The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 25:657–670. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ramezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R and Raj DS: Role of the gut microbiome in uremia: A Potential therapeutic target. Am J Kidney Dis. 67:483–498. 2016. View Article : Google Scholar : PubMed/NCBI
8	Li L, Ma L and Fu P: Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Devel Ther. 11:3531–3542. 2017. View Article : Google Scholar : PubMed/NCBI
9	Chui CH, Cheng GY, Ke B, Lau FY, Wong RS, Kok SH, Fatima S, Cheung F, Cheng CH, Chan AS and Tang JC: Growth inhibitory potential of effective microorganism fermentation extract (EM-X) on cancer cells. Int J Mol Med. 14:925–929. 2004.PubMed/NCBI
10	Yoon SP and Kim J: Exogenous CGRP upregulates profibrogenic growth factors through PKC/JNK signaling pathway in kidney proximal tubular cells. Cell Biol Toxicol. 34:251–262. 2018. View Article : Google Scholar : PubMed/NCBI
11	Kim JB, Hwang SE and Yoon SP: Dexamethasone reduces side population fraction through downregulation of ABCG2 transporter in MCF-7 breast cancer cells. Mol Med Rep. 16:453–458. 2017. View Article : Google Scholar : PubMed/NCBI
12	Okada T and Yoneyama M: The interaction of malignant cells with yeast. II. A new yeast extract inhibiting the growth of malignant cell. Hiroshima J Med Sci. 19:99–117. 1970.PubMed/NCBI
13	Fardon JC, Poydock ME and Tsuchiya Y: Response of neoplastic and non-neoplastic cells to a yeast extract. J Surg Oncol. 10:10–21. 1978. View Article : Google Scholar : PubMed/NCBI
14	Poydock ME, Fardon JC, Tsuchiya Y and Cook ES: Selective effect of fractions of a yeast extract (PCO) on normal and malignant cells. Exp Cell Biol. 46:231–239. 1978.PubMed/NCBI
15	Heffeter P, Jakupec MA, Körner W, Wild S, von Keyserlingk NG, Elbling L, Zorbas H, Korynevska A, Knasmüller S, Sutterlüty H, et al: Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem Pharmacol. 71:426–440. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kim KH, Rodriguez AM, Carrico PM and Melendez JA: Potential mechanisms for the inhibition of tumor cell growth by manganese superoxide dismutase. Antioxid Redox Signal. 3:361–373. 2001. View Article : Google Scholar : PubMed/NCBI
17	Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
18	Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, et al: Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 16:1180–1191. 2014. View Article : Google Scholar : PubMed/NCBI
19	Kazan HH, Urfali-Mamatoglu C and Gunduz U: Iron metabolism and drug resistance in cancer. Biometals. 30:629–641. 2017. View Article : Google Scholar : PubMed/NCBI
20	Yu H, Guo P, Xie X, Wang Y and Chen G: Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med. 21:648–657. 2017. View Article : Google Scholar : PubMed/NCBI
21	Martin-Sanchez D, Poveda J, Fontecha-Barriuso M, Ruiz-Andres O, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A and Sanz AB: Targeting of regulated necrosis in kidney disease. Nefrologia. 38:125–135. 2018.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
22	Fanzani A and Poli M: Iron, oxidative damage and ferroptosis in rhabdomyosarcoma. Int J Mol Sci. 18(pii): E17182017. View Article : Google Scholar : PubMed/NCBI
23	Pfeifhofer-Obermair C, Tymoszuk P, Petzer V, Weiss G and Nairz M: Iron in the tumor microenvironment-connecting the dots. Front Oncol. 8:5492018. View Article : Google Scholar : PubMed/NCBI
24	Golčić M and Petković M: Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer-A new potential biomarker? Med Hypotheses. 94:148–150. 2016. View Article : Google Scholar : PubMed/NCBI
25	Yu CC, Chen KK, Chen MT, Huang JK, Lin AT, Lee YH and Chang LS: Serum iron as a tumor marker in renal cell carcinoma. Eur Urol. 19:54–58. 1991. View Article : Google Scholar : PubMed/NCBI
26	Partin AW, Criley SR, Steiner MS, Hsieh K, Simons JW, Lumadue J, Carter HB and Marshall FF: Serum ferritin as a clinical marker for renal cell carcinoma: Influence of tumor volume. Urology. 45:211–217. 1995. View Article : Google Scholar : PubMed/NCBI
27	Kirkali Z, Esen AA, Kirkali G and Güner G: Ferritin: A tumor marker expressed by renal cell carcinoma. Eur Urol. 28:131–134. 1995. View Article : Google Scholar : PubMed/NCBI
28	Torti SV and Torti FM: Ironing out cancer. Cancer Res. 71:1511–1514. 2011. View Article : Google Scholar : PubMed/NCBI
29	Latunde-Dada GO: Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta Gen Subj. 1861:1893–1900. 2017. View Article : Google Scholar : PubMed/NCBI
30	Santoni M, De Tursi M, Felici A, Lo Re G, Ricotta R, Ruggeri EM, Sabbatini R, Santini D, Vaccaro V and Milella M: Management of metastatic renal cell carcinoma patients with poor-risk features: Current status and future perspectives. Expert Rev Anticancer Ther. 13:697–709. 2013. View Article : Google Scholar : PubMed/NCBI
31	Bayeva M, Khechaduri A, Puig S, Chang HC, Patial S, Blackshear PJ and Ardehali H: mTOR regulates cellular iron homeostasis through tristetraprolin. Cell Metab. 16:645–657. 2012. View Article : Google Scholar : PubMed/NCBI
32	Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C and Czarnecka AM: Choosing the right cell line for renal cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI